A phase IIa clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification

Category Primary study
JournalAnnals of Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 114e101c383123539df235129c6edef632449969
First added on: Feb 11, 2025